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Abstract

23
Phenethylamine-based designer drugs are prevalent within the new psychoactive substance 24 market. Characterisation of their metabolites is important in order to identify suitable 25 biomarkers which can be used for better monitoring their consumption. Careful design of in 26 vitro metabolism experiments using subcellular liver fractions will assist in obtaining reliable 27 outcomes for such purposes. The objective of this study was to stepwise investigate the in benzodioxolyl-butanamine, 5-(2-aminopropyl)benzofuran and 6-(2-aminopropyl)benzofuran.
32
Identification and structural elucidation of the metabolites was performed using liquid glucuronide (Naphth-Gluc; neat, purity>99%), 5-bromo-4-chloro-3-indolyl sulfate (Indolyl-
127
Sulf; neat, purity>99%) and NADPH (neat, purity>99%) were purchased from Sigma-
128
Aldrich (Diegem, Belgium). Ultrapure water was prepared using a Purelab flex water system 129 by Elga (Tienen, Belgium). Acetonitrile, methanol, ammonium hydroxide, hydrochloric acid
130
and ammonium acetate were purchased from Merck (Darmstadt, Germany). All organic 131 solvents were HPLC grade or higher. 
Tiered approaches on in vitro drug metabolism
133
In this study, a two-tiered approach for investigating Phase I and Phase II in vitro drug about the catalytic activity of major human liver CYPs was provided by the HLM vendor.
201
Three different negative control samples were prepared by omitting the enzymes, the substrate, or the cofactor in the reaction mixture. The negative control samples for CYP,
203
UGT and SULT activity were prepared as described in tier I section above. evaluating in vitro data on human drug metabolism with in silico methods [26] .
248
The chromatographic features of each compound, such as the retention time and peak reactions that the family of enzymes under investigation is able to catalyse; and (f) the 259 retention time of the detected metabolites should not be higher than that of the parent drug.
260
Tier II data are presented as the response value, which was calculated as the peak area ratio of 261 the metabolite or the parent drug to the internal standard (theophylline) for compensating 262 inter-sample and instrumental variability during analysis. approximately 10 min earlier than the parent compound, suggesting that it has a higher polarity than PMA, in agreement with the formation of a hydroxylated metabolite. PMA-M1
281
was not detected in any of the three negative control samples, confirming it to be a metabolite 282 produced by CYP enzymes.
283
In tier IA samples, two metabolites of PMMA were detected ( Table 2) (Table   293 2), which represented the metabolite produced by N-demethylation of PMMA by CYP 294 enzymes (Fig. 3B ). The structure of PMMA-M2 can be explained by three major product ions 295 and the feature of the alkylbenzene moiety ( Fig. S3B ). Also, 4-MTA-M2 eluted about 13 min earlier 349 than 4-MTA (Table 3 ), suggesting that it is a more polar compound than the substrate. (Table 3) . 4-MTA-M3 eluted about five min later than 358 4-MTA-M2 (Table 3) , suggesting it is a less polar compound than 4-MTA-M2.
359
The 4-MTA-M4 precursor ion was m/z 199.0787 with the measured DBE value at 4 360 ( Table 3 , Fig. S3D ), corresponding to a di-hydroxylated metabolite of 4-MTA from reduction 361 of 4-MTA-M3 (Fig. 3C) . The molecular structure of 4-MTA-M4 was similar to that of 4- were not conducted. 
Discussion
417
This study successfully investigated the formation and characterisation of in vitro 418 metabolites of seven phenethylamine-based designer drugs using HLM and LC-QTOF-MS.
419
In tier IA, structures of the possible metabolites were predicted through interpreting the 
483
This study revealed that 4-MTA was largely metabolised into four metabolites (Table 3) 484 and a clear trend of their formation was observed (Fig. 5) . The results also suggest that the (Table S1 ) with a few minor metabolites identified 508 which were formed via oxidative deamination followed by reduction to corresponding proceeds at a very slow pace. Furthermore, the lack of detection of any metabolites for BDB,
527
5-APB and 6-APB reinforces the role of methylation of the amino group in favouring the in 528 vitro metabolism for this group of drugs as this moiety is the major structural difference 529 among them.
530
The results of this study are partially in line with other metabolism studies for these four showing that glucuronidated and sulfated conjugated metabolites of MBDB and BDB were 541 not detected in the in vitro experiments using particular isoenzymes of human and rat [21] .
542
These results overall suggest that conjugation of MBDB and BDB appears not to be a major (Table S1 ). Similar to the present in vitro study, 5-
551
APB and 6-APB were not degraded by activated sludge (own unpublished data). These 552 findings suggest that these two drugs are rather resistant to enzymatic and bacterial 553 digestions.
554
In vitro metabolism data of the selected designer drugs are important for drug-related 555 disciplines, such as forensic toxicology, since they provide key compounds useful to better 556 identify these drugs in humans and crime scenes. Also, the results of the current study reveal 557 potential human biomarkers of the targeted designer drugs to be measured in urine from 558 individuals, pooled urine samples or even wastewater samples for assessing the use of these 559 designer drugs in the emerging research field of wastewater-based drug epidemiology [46] .
560
Since the data indicated that the in vitro metabolism of the targeted designer drugs proceeds 561 at slow rate, the parent drug itself appears to be the key biomarker in most cases. However,
562
for PMA and PMMA, the respective para-hydroxylated metabolite can be considered as its 
756
C and F), the enzyme concentration was kept at 0.8 mg/mL and the experimental time was conducted for 90 757 min. See Tables 1 and 2 for the molecular structures of the metabolites. 
779
with the change in the substrate concentrations (i.e. C), the enzyme concentration was kept at 0.8 mg/mL and
